Contact

Why Some Patients Overpay for Specialty Generic Drugs

Crosson FJ, Kesselheim AS - JAMA Internal Medicine

  • Commentary & Opinion
| January 2024
  • Innovation Incentives and Competition
  • Price, Value, and Access
  • Regulation and Clinical Evidence

Summary:

The authors discuss the Hatch-Waxman Act framework for generic drug competition, and the distortions in the pharmaceutical supply chain that can keep generic drug prices high years after the end of market exclusivity for the branded originator.

VIEW SOURCE
Talk bubble graphics representing commentary and opinion.

LEARN MORE

BROWSE COMMENTARY & OPINION

Recent Work from PORTAL

Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing

Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics

  • Research Publications
| November 2026
  • Price, Value, and Access
View Source
Talk bubble graphics representing commentary and opinion.

How Congress Can Fix Expert Advisory Committees

Daval CJR, Kesselheim AS - STAT

  • Commentary & Opinion
| October 2026
  • Regulation and Clinical Evidence
View Source
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty

Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open

  • Research Publications
| October 2026
  • Price, Value, and Access
View Source
VIEW MORE

Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115

©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.